ATR and neoplasm: The development of a high throughput screening, based on a recombinant ATR kinase allowing the combination of a structure–activity relationship and homology modeling studies, led to the discovery of the first series of potent and selective ATR inhibitors [89], with one of them, VE-821, further progressing preclinical evaluation as a sensitizer of radiotherapy and chemotherapy treatments in several tumor models.